ASCO 2016: Updated Phase 1b Study Data on Mesothelioma Drug Presented by Five Prime Therapeutics
News
At the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Five Prime Therapeutics revealed updated results from the ongoing Phase 1b clinical trial of FP-1039 (GSK3052230) for the treatment of ... Read more